DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05722886 |
|
Recruitment Status :
Recruiting
First Posted : February 10, 2023
Last Update Posted : March 20, 2024
|
Sponsor:
Cancer Research UK
Collaborators:
University of Manchester
University of Birmingham
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche
Information provided by (Responsible Party):
Cancer Research UK
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2029 |
| Estimated Study Completion Date : | October 2029 |